Annual Report And Consolidated Financial Statements

Overview

The report describes 2024 as a transformative year following the reverse takeover that created the enlarged CRISM Group. The company advanced its ChemoSeed drug-delivery programme toward a UK clinical trial authorisation, signed a development services contract, and received a European patent grant. The Group reported a £607,000 loss for the year, alongside continued research and development and regulatory activity.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Publication date: 12 June 2025
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services